Overview
Perception Neuroscience is developing arketamine (R-ketamine) as a rapid-acting antidepressant with a potentially more favorable side-effect profile than esketamine. Their program targets treatment-resistant depression and suicidal ideation.
More in Mental Health Tech
Latest industry news
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
Company details
Category
💙 Mental Health Tech
Location
New York, USA
Funding
Series A · $15M
Website
perceptionneuroscience.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →